Aztreonam lysine for inhalation
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic_medication
gptkb:inhaled_drug |
| gptkbp:activeIngredient |
gptkb:aztreonam
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J01DF01
|
| gptkbp:brand |
gptkb:Cayston
|
| gptkbp:contraindication |
hypersensitivity to aztreonam
|
| gptkbp:form |
lyophilized powder for solution
inhalation solution |
| gptkbp:indication |
cystic fibrosis with Pseudomonas aeruginosa infection
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:sideEffect |
fever
cough nasal congestion wheezing pharyngolaryngeal pain |
| gptkbp:bfsParent |
gptkb:Corus_Pharma
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aztreonam lysine for inhalation
|